Abstract
In this pilot study, we have investigated the effects of switching from olanzapine or risperidone treatment to low-dose perphenazine combined with buspirone in six schizophrenic patients who had experienced weight gain. We found no relapse as to psychotic symptoms measured by the CGI-S scale and no exacerbation of extrapyramidal side-effects as measured by the Simpson-Angus Scale. In addition, we observed a medium weight reduction of 10.5 kg (range 1-20 kg).
MeSH terms
-
Adult
-
Antipsychotic Agents / therapeutic use*
-
Basal Ganglia Diseases / chemically induced*
-
Benzodiazepines / therapeutic use
-
Buspirone / therapeutic use*
-
Denmark
-
Drug Therapy, Combination
-
Female
-
Humans
-
Male
-
Middle Aged
-
Olanzapine
-
Perphenazine / therapeutic use*
-
Pilot Projects
-
Risperidone / therapeutic use*
-
Schizophrenia / drug therapy*
-
Schizophrenic Psychology*
-
Serotonin Receptor Agonists / therapeutic use*
-
Weight Loss / drug effects*
Substances
-
Antipsychotic Agents
-
Serotonin Receptor Agonists
-
Benzodiazepines
-
Perphenazine
-
Risperidone
-
Olanzapine
-
Buspirone